Comparing the Efficacy of Fluvoxamine and Sertraline in Treating Major Depressive Disorder (MDD)

Document Type : Original Article (s)

Authors

1 Instructor, Department of Experimental Sciences, Islamic Azad University, Yazd Branch, Yazd, Iran

2 General Practitioner, Scientific Society of Medicine, Islamic Azad University, Yazd Branch, Yazd, Iran

3 Assistant Professor, Department of Psychiatry, Islamic Azad University, Yazd Branch, Yazd, Iran

4 Assistant Professor, Department of Neurology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Abstract

Background: Major depressive disorder (MDD) is a common psychiatric disorder that 16.2 of population in developed countries experience it at least once in their lifetime; it is a major cause of social disability according to WHO reports. This study was designed to compare the efficacy of fluvoxamine and sertraline in treating major depressive disorder.Methods: During this randomized clinical trial, 110 patients with certain diagnosis of major depressive disorder were divided in two parallel groups: fluvoxamine 200 mg daily and sertraline 100 mg daily. Beck test was done before and after intervention and the data were analyzed by chi-square and independent-sample t tests.Findings: 58 patients (52.72%) received fluvoxamine and 52 (47.28%) received sertraline. Fluvoxamine had better therapeutic effects than sertraline (P = 0.002). Although, women (P = 0.007) and age group of 43-67 years (P = 0.015) had better response to fluvoxamine.Conclusion: According to current findings, it is recommended that gender and age group be noticed in administrating the selective serotonin re-uptake inhibitors (SSRI) drugs in patients with major depressive disorder.

Keywords

References

  1. Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr 2007; 12(8 Suppl 13): 1-27.
  2. World Health Organization. Depression [Online]. [cited 2008 Sep]; Available from URL: http://www.who.int/mental_health/management/depression/definition/en/.
  3. Tasman A, Kay J, Lieberma JA. Psychiatry: Therapeutics. 2nd ed. Hoboken, NJ: John Wiley & Sons, Ltd.; 2003.
  4. National Collaborating Centre for Mental Health. Depression: management of depression in primary and secondary care (Clinical Guideline 23). London, UK: National Institute for Clinical Excellence; 2004.
  5. Ballas C, Staab JP, Evans DL. Strategies for treatment-resistant depression. Psychopharmacol Bull 2002; 36(4): 39-62.
  6. Golubchik P, Kodesh A, Weizman A. Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood? Clin Neuropharmacol 2013; 36(5): 141-5.
  7. Khan A, Faucett J, Morrison S, Brown WA. Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry 2013; 70(10): 1091-9.
  8. Herzallah MM, Moustafa AA, Natsheh JY, Danoun OA, Simon JR, Tayem YI, et al. Depression impairs learning, whereas the selective serotonin reuptake inhibitor, paroxetine, impairs generalization in patients with major depressive disorder. J Affect Disord 2013; 151(2): 484-92.
  9. Leuchter AF, Husain MM, Cook IA, Trivedi MH, Wisniewski SR, Gilmer WS, et al. Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med 2010; 40(2): 239-51.
  10. Fernandez CA, Galor A, Arheart KL, Musselman DL, Venincasa VD, Florez HJ, et al. Dry eye syndrome, posttraumatic stress disorder, and depression in an older male veteran population. Invest Ophthalmol Vis Sci 2013; 54(5): 3666-72.
  11. Veen G, Giltay EJ, Licht CM, Vreeburg SA, Cobbaert CM, Penninx BW, et al. Evening salivary alpha-amylase, major depressive disorder, and antidepressant use in the Netherlands Study of Depression and Anxiety (NESDA). Psychiatry Res 2013; 208(1): 41-6.
  12. Stein DJ, Lopez AG. Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. Adv Ther 2011; 28(11): 1021-37.
  13. Henigsberg N, Bajs M, Hrabac P, Kalember P, Rados M, Rados M, et al. Changes in brain metabolites measured with magnetic resonance spectroscopy in antidepressant responders with comorbid major depression and posttraumatic stress disorder. Coll Antropol 2011; 35(Suppl 1): 145-8.
  14. Uguz F. Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. J Matern Fetal Neonatal Med 2013; 26(11): 1066-8.
  15. Dalery J, Honig A. Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison. Hum Psychopharmacol 2003; 18(5): 379-84.
  16. Baumert M, Lambert GW, Dawood T, Lambert EA, Esler MD, McGrane M, et al. QT interval variability and cardiac norepinephrine spillover in patients with depression and panic disorder. Am J Physiol Heart Circ Physiol 2008; 295(3): H962-H968.
  17. Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC, Jr., et al. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2008; 28(2): 235-9.
  18. Davis LL, Wisniewski SR, Howland RH, Trivedi MH, Husain MM, Fava M, et al. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend 2010; 107(2-3): 161-70.
  19. Stokes PE. Fluoxetine: a five-year review. Clin Ther 1993; 15(2): 216-43.
  20. Franchini L, Gasperini M, Zanardi R, Smeraldi E. Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate. J Affect Disord 2000; 58(3): 233-6.
  21. Rossini D, Serretti A, Franchini L, Mandelli L, Smeraldi E, De RD, et al. Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. J Clin Psychopharmacol 2005; 25(5): 471-5.
Journal of Isfahan Medical School
Volume 31, Issue 256 - Serial Number 256
September and October 2013
Pages 1620-1627

Files

History

  • Receive Date: 13 December 2012
  • Revise Date: 23 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics